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Abstract
Background: The aim of the present study was to estimate the effectiveness of the MF59TM-adjuvanted influenza
A(H1N1)pdm09 vaccine against medically attended influenza-like illness and RT-PCR confirmed influenza in the at-risk
population and persons over 60 in the Netherlands.
Methods: We conducted a retrospective cohort study in a Dutch based GP medical record database between 30 November
2009 and 1 March 2010 to estimate the vaccine effectiveness against influenza-like illness. Within the cohort we nested a
test negative case-control study to estimate the effectiveness against laboratory confirmed influenza.
Results: The crude effectiveness in preventing diagnosed or possible influenza-like illness was 17.3% (95%CI:28.5%–36.9%).
Of the measured covariates, age, the severity of disease and health seeking behaviour through devised proxies confounded
the association between vaccination and influenza-like illness. The adjusted vaccine effectiveness was 20.8% (95%CI:25.4%,
40.5%) and varied significantly by age, being highest in adults up to 50 years (59%, 95%CI: 23%, 78%), and non-detectable in
adults over 50 years. The number of cases in the nested case control study was too limited to validly estimate the VE against
confirmed influenza.
Conclusions: With our study we demonstrated that the approach of combining a cohort study in a primary health care
database with field sampling is a feasible and useful option to monitor VE of influenza vaccines in the future.
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Introduction
Vaccination is regarded as one of the most efficient interven-
tions that protect the population at risk of serious health
complications during influenza pandemics [1]. During the
H1N1-influenza pandemic of 2009/2010 mass vaccination cam-
paigns with new influenza vaccines were set out throughout the
world. In order to reduce the amount of antigen needed for
vaccinating entire populations oil-in-water adjuvanted vaccines
were used for the first time on a large scale in Europe [2]. In the
Netherlands general practitioners (GPs) were provided with
MF59TM-adjuvanted influenza A(H1N1)pdm09 vaccines [3] to
vaccinate persons at risk due to underlying comorbidities and
persons over 60 years of age. These persons were offered two doses
of the vaccine.
The MF59-adjuvanted influenza A(H1N1)pdm09 vaccine was
licensed based on immunogenicity and safety of vaccines with
avian influenza strains, allowing for fast track roll out of vaccines
upon the emerging pandemic [2]. Estimates of the effectiveness of
the vaccine in targeted risk groups are scarce to date [4,5,6].
Steens et al reported no significant vaccine effectiveness (VE) (19%,
95%CI: 228, 49) against influenza A(H1N1)pdm09 -infection
related hospitalisation in a matched case control study in targeted
risk groups in the Netherlands [4]. Castilla et al [5] conducted a
cohort study in all non-institutionalized persons in a region in
Spain where children (1–17 years) and persons aged over 60
received the MF59TM-adjuvanted influenza A(H1N1)pdm09
vaccine. They found no evidence of effectiveness of vaccination
against medically attended influenza-like illness (ILI) in children
(VE: 12%; 95%CI: 2142%, 68%) and in the elderly (VE: 25%;
95%CI: 219%, 53%).
Data on effectiveness of vaccination programmes with adju-
vanted vaccines in different target groups is essential to inform
future decisions and recommendations for vaccination pro-
grammes and possible complementary or alternative public health
measures in order to mitigate the potential impact of influenza
epidemics and pandemics. The aim of our study was to estimate
the effectiveness of the MF59TM-adjuvanted influenza
A(H1N1)pdm09 vaccine against medically attended ILI and
against laboratory confirmed A(H1N1)pdm09 infection in the
population that was indicated for vaccination by the GP in the
Netherlands.
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Methods
We conducted a retrospective cohort study in a Dutch GP medical
record database, in which we nested a case control study to determine
effectiveness of the MF59TM-adjuvanted influenza A(H1N1)pdm09
vaccine against RT-PCR confirmed influenza infection.
IPCI Database
Our cohort was identified within the Integrated Primary Care
Information (IPCI) database. More detailed information on IPCI
has been published elsewhere [7]. In short, IPCI contains
longitudinal data from anonymized computer-based medical
records of Dutch GPs from 1996 onwards. In the Netherlands,
almost all residents are registered with a GP or practice, which
serves as the gatekeeper to and from all medical care in the
Netherlands. The age and gender distribution of the population in
IPCI is representative of the Netherlands and of community
dwelling persons. Currently, IPCI contains information on over
1,100,000 patients from over 200 participating GP practices
located throughout the Netherlands. IPCI includes anonymous
demographic information as well as information on signs,
symptoms and diagnoses, both coded through the International
classification of primary care (ICPC) and as free text, prescriptions
(ATC coded), annual vaccinations against influenza and non-
childhood vaccines, hospital admissions, referrals to secondary
care, letters from specialists, and laboratory test results. Records
have good validity for prescriptions, hospitalizations, influenza
vaccination and influenza related outcomes [7,8,9]. The IPCI
database complies with European Union guidelines on the use of
medical data for medical research [7]. Approval for this study was
obtained by the Scientific and Ethical Advisory Board of the IPCI
project and by the Medical Ethical committee of Erasmus MC.
Informed consent was obtained from all patients participating in
the nested case control study.
Study Population
Cohort. We defined a cohort within the IPCI database of
persons who were eligible for A(H1N1)pdm09 vaccination through
the GP due to an underlying medical condition or age .60 years
and who had at least one year of valid database history. As
pregnancy is not consistently recorded from the start of pregnancy,
only pregnant women indicated for A(H1N1)pdm09 vaccination
due to underlying medical conditions were included in the cohort.
Eligibility for vaccination was assessed from the electronic patient
records using free text and ICPC-code searches followed by
manual verification in the full electronic medical record.
We excluded GPs with incomplete or unreliable registration of
vaccination defined as a coverage of influenza A(H1N1)pdm09
vaccine in persons .60 years lower than 50%, or with unreliable
vaccination dates. In addition, we excluded persons with a
contraindication to influenza vaccination and persons who had
visited the GP for ILI between start of circulation of H1N1 in the
Netherlands (week 28) and start of follow-up (week 49).
Nested case control. Practices included in the cohort study
were invited to participate in the case control study. Cases and
controls were obtained from cohort members who visited the GP
for ILI during the study period. Controls were to be matched to
cases by GP practice and time of presentation.
Study Period
Cohort. Follow-up started on 30 November 2009 (week 49),
two weeks after the majority of GP practices had administered the
1st dose. Follow-up ended at death, first ILI, transferring out of the
practice, or end of the study period (1 March 2010).
Nested case control. The swab schedule for the nested case
control study was planned to start two weeks after start vaccination
as indicated by participating GPs. Swabbing started on 9
November 2009 and ended on 3 March 2010.
Study Endpoint
Cohort. The outcome of interest was medically attended ILI
using the European ILI case definition [10]: a sudden onset of
symptoms combined with 1) at least one of the following
symptoms: fever or feverishness, malaise, headache, or myalgia;
and 2) at least one of the following three respiratory symptoms:
cough, sore throat, shortness of breath.
ILI cases were extracted from the IPCI database by using an
extensive string search including free text terms combined with
ICPC-codes (R80, R81, R74, R78) reflecting the symptoms and
diagnosis of ILI. Obvious negations were excluded. All identified
ILI cases from week 30 onwards were manually validated against
the full electronic patient record to check whether they met the
case definition, validation was done while being blinded to
exposure.
Nested case control. The primary outcome in the case
control study was RT-PCR confirmed influenza in persons
presenting to the GP with ILI. A nasopharyngeal swab was taken
from cohort members with ILI symptoms during the influenza
season. Nasopharyngeal swabs were sent to the virology depart-
ment of the Erasmus-MC for RT-PCR analysis. All persons with
samples tested positive for influenza infection were classified as
cases. Cases were sub-typed as influenza A(H1N1)pdm09, H1N1,
H3N2 or B. Persons with ILI but no detectable influenza were
classified as controls.
Exposures
The primary exposure of interest in this study was vaccination
with MF59TM-adjuvanted influenza A(H1N1)pdm09 vaccine.
Persons having received at least a first dose of vaccine at the
start of follow-up (cohort) or at time of swabbing (nested case
control) were considered exposed, regardless of the time since
vaccination. Vaccination status was determined through GP-
specific free text searches and ICPC-codes in the full electronic
patient record followed by random manual verification to assess
and increase the specificity of the final search. Distinction between
seasonal influenza vaccination and doses of H1N1-vaccinations
were based on free text wording and calendar dates. Information
on the following covariates at baseline was collected from the
electronic patient record for each individual in the cohort: age,
gender, presence of co-morbidity (diabetes, respiratory, cardiovas-
cular, renal insufficiencies, immune-compromised or malignan-
cies; identified through free text searches and ICPC-codes followed
by manual verification against the electronic records), seasonal
influenza vaccination history, use of oseltamivir, zanamivir,
amantadine, rimantadine, health care utilization (defined as
number of GP-visits in previous year) and severity of underlying
comorbidity (estimated by the number of different drugs
prescribed in previous year identified by number of different
ATC-codes).
Participants in the nested case control study had a unique study
ID that was linked to their unique patient identifier in the IPCI
database. Information on exposure and covariates was extracted
from the IPCI-database.
Statistical Methods
Cohort. Descriptive analyses and univariate analysis were
performed to compare study population baseline characteristics
between vaccinated and unvaccinated patients. We estimated
Adjuvanted Pandemic Vaccine Effectiveness
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crude and adjusted estimates for VE (1-relative risk*100%) for
ILI through univariate and multivariate Cox-proportional
hazard analysis. We used subject time, which was calendar
time, as the time axis. Variables were included in the
multivariate analysis if they changed the crude point-estimate
by more than 10%.
Nested case control. Crude odds ratios with 95% confi-
dence intervals were obtained by using conditional logistic
regression analysis. The crude VE was computed as VE = 1– OR.
Sensitivity analyses. In the cohort, misclassification of
exposure was investigated by varying the start of the follow-up
period (starting at week 47 and week 51 instead of 49), and
varying the definition of exposure. In this analysis persons were
considered exposed if they were vaccinated .14 days prior to
baseline or .7 days prior to baseline. All other persons were
considered unexposed. Additionally, we conducted a post hoc
analysis in which vaccination was considered as a time
dependent variable, meaning the exposure status was deter-
mined when an outcome occurred. Persons were considered
exposed 14 days after vaccination. In this analysis baseline could
be brought back to 01-10-2009, which increased the number of
cases. As vaccination was time dependent misclassification was
also minimized.
Statistical significance was accepted at a p-value ,0.05. All
analyses were done using SPSS (SPSS Inc., Chicago, IL, USA)
version 15.0 for Windows.
Results
Study Population
Cohort. At the start of follow-up there were 191,518 persons
who had an indication for influenza A(H1N1)pdm09 vaccination
in 205 GP practices contributing data to IPCI. Of these, 68,642
persons from 102 GP practices were excluded, as influenza
A(H1N1)pdm09 vaccination could not be assessed reliably in the
electronic patient record. Of the remaining 122,876 persons, 1,430
had ILI between week 28 and start of follow-up (week 49) and
were excluded as they were not at risk of H1N1 ILI anymore
(assuming infection with H1N1). The final study population for the
primary analysis included 121,446 patients with an average follow-
up time of 75.8 days per person (SD 22.2) from week 49 onwards.
Nested case control. In total, 41 GP practices agreed to
participate in the nested case control study. Two dropped out early
due to time constraints.
Baseline Characteristics Cohort
The A(H1N1)pdm09 vaccinated and non-vaccinated persons
differed regarding a number of baseline characteristics (Table 1).
Unvaccinated persons were younger and less likely to have
received a seasonal influenza vaccine in 2008 and 2009. The
majority of the cohort (73.5%) had at least one type of underlying
disease that would qualify as indication for vaccination, thus
including healthy people 60 years or older. With the exception of
diabetes and respiratory disease, co-morbidities were more
prevalent in vaccinated as compared to unvaccinated persons,
most notably for cardiac disease and malignancies. The mean
number of different drugs prescribed in the preceding year was
higher in vaccinated persons, as was the number of GP contacts in
the preceding year.
Vaccination
Vaccine uptake was highest in persons 60 years and older
(Figure 1). By the end of the vaccination campaign, 88% of those
having received a first dose also received a second dose of the
influenza A(H1N1)pdm09 vaccine. At the start of follow-up, which
was before the end of the vaccination campaign, point coverage
for seasonal influenza vaccination in the cohort was 59.8%. For a
single dose of influenza A(H1N1)pdm09 vaccine it was 57.6% and
for two doses it was 4.2% (Figure 2). Fifty-one % of vaccinated
persons had received a first dose at least 14 days before the start of
the study. Only 16% had received their first dose less than 7 days
before the start of the study.
ILI & RT-PCR Confirmed Influenza
In the total cohort, 255 ILI cases were identified during follow
up. The incidence rate of ILI during follow-up was age dependent,
being highest in the youngest age group and slightly lower in
subsequent age groups (Table 2). The overall incidence rate during
follow-up was 10.1 per 1000 person years (95%CI: 8.9–11.4).
Figure 2 shows the distribution of validated ILI cases, influenza
positive and negative cases from the case control study over
calendar time along with the coverage of the first and second dose
of pandemic influenza vaccination. Vaccination started around the
peak of ILI incidence.
In the nested case control study 46 swabs were received for
analysis. One swab could not be analysed. Of the remaining 45, 9
tested positive for influenza A, including 7 confirmed
A(H1N1)pdm09 infections. The average age of cases was 33.4
years (SD: 22.3 years), controls were older with an average age of
55.4 years (SD 20.5 years).
Vaccine Effectiveness
In the total cohort, we found a crude VE estimate against ILI of
17.3% (95%CI: 28.5%, 36.9%). Of the measured covariates, age,
the number of different drugs prescribed in the preceding year and
the number of GP contacts in the preceding year confounded the
association between influenza A(H1N1)pdm09 vaccine and ILI
with at least a 10% change in the point estimate. The adjusted VE
against ILI was 20.8% (95%CI: 25.4%, 40.5%) (table 3). The VE
differed by age groups, with the highest adjusted VE in adults up
to 50 years (59%, 95%CI: 23%,78%).
Based on the 9 cases and 36 controls in the nested case control
study, we estimated a crude VE for the influenza A(H1N1)pdm09
vaccine in preventing RT-PCR confirmed influenza was 73.3%
(95%CI: 4.8%, 92.5%). The crude VE against RT-PCR
confirmed influenza A(H1N1)pdm09 infection was 88% (95%CI:
25%, 98%). Due to the small sample size, no adjusted or matched
analysis was performed.
Sensitivity Analyses
In the primary analysis everyone who had received an influenza
A(H1N1)pdm09 vaccine at the start of follow-up or at time of
swabbing was considered exposed regardless of time since
vaccination. As it takes 2 to 3 weeks to mount an immune
response to seasonal influenza vaccines [11], in our primary
analysis persons could have been considered exposed whilst they
were not immunized. To address this potential misclassification we
restricted the definition of exposure and only considered those as
exposed who received a first dose more than 7 days before
baseline, non-exposed were persons who were not vaccinated or
vaccinated within 7 days. This decreased the crude VE against ILI
to 13.3% (95%CI: 215.5%–34.9%). Only considering as exposed
those who received a first dose more than 14 days before baseline
and as non-exposed those not vaccinated or vaccinated within 14
days prior to baseline decreased this estimate further to 5.1%
(95%CI: 236.1%, 33.8%). Restricting the analysis of the nested
case control study to swabs taken 14 days after the start of
vaccination resulted in a crude VE against RT-PCR confirmed
Adjuvanted Pandemic Vaccine Effectiveness
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influenza A infection of 17% (95%CI 2563%, 90%) and a crude
VE against influenza A(H1N1)pdm09 infection of 75% (95%CI:
2473%, 99%).
The baseline for the cohort study was chosen relatively late
(figure 2) to allow for the majority of GP-practices to have
administered at least the first dose of influenza A(H1N1)pdm09
vaccine plus 14 days for the vaccine to exert its effectiveness. When
applying a start of follow-up two weeks earlier (week 47 instead of
week 49) the crude overall VE increased to 23% (95%CI: 4%,
38%). Applying a cut-off two weeks later (week 51 instead of week
49) decreased the crude overall VE to 27.8% (95%CI: 248.0%,
22.4%).
In a post-hoc analysis we started follow-up in October 2009 and
considered exposure to A(H1N1)pdm09 vaccination to be a time
dependent variable. By doing so misclassification of exposure is
limited. The most noticeable increase in number of cases was seen
in the #4 year age group. Overall, the estimates move closer
towards no effect (table 4).
Discussion
In our retrospective cohort study we found an overall small non-
significant protective effect of vaccination with an MF59TM-
adjuvanted influenza A(H1N1)pdm09 vaccine against ILI. The
VE estimates against RT-PCR confirmed influenza and
A(H1N1)pdm09 infection were substantially higher, however
Table 1. Baseline characteristics cohort.
Exposed to first dose influenza A(H1N1)pdm09 vaccine6
unexposed Exposed
51442 70004
n (%) n (%) p-value
Age1 Mean (st.dev) 49.8 (22.5) 63.6 (16.8) ,0.0001
,= 4 938 (1.8) 371 (0.5)
5–19 6717 (13.1) 2445 (3.5)
20–49 14266 (27.7) 7216 (10.3)
50–59 7223 (14.0) 7315 (10.4)
60–79 18809 (36.6) 43235 (61.8)
80+ 3489 (6.8) 9422 (13.5)
Gender male 24720 (48.1) 32290 (46.1) ,0.0001
Seasonal influenza vaccination 2009 12744 (24.8) 59965 (85.7) ,0.0001
Seasonal influenza vaccination 2008 15153 (29.5) 51522 (73.6) ,0.0001
Number of pandemic H1N1 vaccine doses on 30-11-09 None 51442 (100)
1 dose 67048 (95.8)
2 doses 2956 (4.2)
Mean number of days since first dose (SD)
Days since first dose on 30-11-2009 ,7 11568 (16.5)
7–14 31420 (44.9)
$14 35494 (50.7)
Diabetes 16063 (31.2) 16269 (23.2) ,0.0001
Cardiac disease 12752 (24.8) 32781 (46,8) ,0.0001
Respiratory disease 12208 (23.7) 18840 (26,9) ,0.0001
Renal disease 884 (1.7) 2218 (3.2) ,0.0001
Malignancy 4929 (9.6) 10717 (15.3) ,0.0001
Immune compromised 95 (0.2) 199 (0.3) ,0.0001
Any chronic co-morbidity3 36334 (70.6) 53012 (75.7) ,0.0001
Mean number of different drugs prescribed2,4 Mean (st.dev) 3.69 (4.1) 6.0 (4.9) ,0.0001
Mean number of GP contacts2 Mean (st.dev) 11.0 (11.6) 17.3 (13.2) ,0.0001
Use of antiviral drugs5 before 30-11-2009 130 (0.3) 246 (0.4) 0.002
Use of antiviral drugs5 after 30-11-2009 13 (0.0) 38 (0.1) 0.015
1On 30-11-2009.
2Between 01-10-2008 and 01-10-2009.
3Includes respiratory, cardiovascular, diabetes and renal disease, persons with malignancies and immune compromised.
4Based on ATC (7 digits).
5Antiviral drugs: Amantadine, rimantadine, oseltamivir, zanamivir which are all indicated for treatment of influenza infection; amantadine is also used in the treatment of
parkinsons disease.
6In the analyses those with ILI prior to start of follow-up (30-11-09) were excluded.
doi:10.1371/journal.pone.0063156.t001
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Figure 1. Vaccination coverage per age group. Vaccination coverage per age group for seasonal influenza vaccination and first and second
doses of influenza A(H1N1)pdm09 vaccine in the cohort of patients that had an indication for pandemic influenza vaccination.
doi:10.1371/journal.pone.0063156.g001
Figure 2. Influenza vaccination in relation to the pandemic curve. Coverage of the 1st and 2nd dose of the influenza A(H1N1)pdm09 vaccine,
ILI cases in the cohort, and influenza positive cases plus controls (influenza negative) from the nested case control study against calendar time.
doi:10.1371/journal.pone.0063156.g002
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numbers were small estimates are relatively unstable and no
adjusted analysis could be performed. Limited importance should
be attached to this crude estimate as it may suffer from
confounding.
The adjusted VE against ILI was highest in persons between the
age of 20 and 49 years (59%; 95%CI: 20%–78%) and in children
between the age of 5 and 19 years (adjusted VE: 51%; 95% CI:
250% to 84%). We could not validly estimate the vaccine
effectiveness in children #4 years as the group was very small and
vaccinations could have been received through other routes than
the GP. For persons between 50 and 59 years and persons between
60 and 79 years the adjusted VE was 21% (95% CI: 280%–64%),
and 215% (95% CI: 290%–30%) respectively.
This is in line with findings from a large study by Castilla et al
[5], who conducted a cohort study in children (1–17 years) and
persons over 60 years, evaluating the VE of the MF59TM-
adjuvanted influenza A(H1N1)pdm09 vaccine against medically
attended ILI. Similar to our findings, the VE in persons over 60 in
their study was 25% (95%CI: 219%, 53%).
Immunosenescence resulting in reduced VE in older age groups
is a known problem for seasonal inactivated influenza vaccines and
adjuvants have been brought up as a possible solution [12]. As in
the study by Castilla et al we found no evidence that the
adjuvanted vaccine results into improved effectiveness against
ILI in the elderly. A possible explanation of the absence of
effectiveness against ILI in persons over 50 in our study is the lack
of specificity of ILI for influenza, due to the presence of cross-
reactive antibodies in older adults resulting from previous
exposure to similar influenza strains [13]. These would protect
against infection with influenza A(H1N1)pdm09 regardless of
vaccination, whilst still being susceptible to a wide range of
pathogens that could cause ILI. As a result ILI could be less
specific for influenza in older people than in younger people who
lack cross-reactive antibodies [13] leaving them vulnerable to
influenza A(H1N1)pdm09 infection, hence a proportion of ILIs
could be caused by influenza virus. Consequently, the specificity of
ILI could not only change with time, as circulation of virus
decreases, but also with age. These uncertainties underline the
importance of including confirmed influenza infection as an
endpoint to validate findings in the larger cohort. In our nested
case control study we lacked the power to do this.
A test negative case control study evaluated the VE of the
MF59TM-adjuvanted influenza A(H1N1)pdm09 against laboratory
confirmed influenza A(H1N1)pdm09 infection in a general
population $10 years of age in Korea. Only14% had underlying
disease. They found a VE of 73.4% (95%CI: 49.1%, 86.1%)
against laboratory confirmed influenza A(H1N1)pdm09 infection
[6], which did not vary significantly with age, supporting the
theory that our findings are due to the lack of specificity of our
endpoint rather than the vaccine. However, considering the
differences in population ideally we would have validated this
within our own cohort.
Several studies evaluated the effectiveness of ASO3-adjuvanted
influenza A(H1N1)pdm09 vaccine against laboratory confirmed
H1N1 in the general population [14,15,16,17,18,19], reporting
VE estimates between 60% and 95%. The effectiveness of AS03-
adjuvanted influenza A(H1N1)pdm09 vaccine was found to be
lower in an at risk population under 65 in Denmark (49% against
laboratory confirmed ILI, 44% against hospitalisation) [18]. Other
studies for a mix of adjuvanted and non-adjuvanted vaccines
against ILI, laboratory confirmed H1N1 and hospitalisations
[20,21,22,23,24] reported combined VE estimates of 52% against
ILI [20], 72% to 95% against lab confirmed ILI [21,22,23,24] and
90%–100% against hospitalisations [21,23].
In our cohort, severity of underlying co-morbidity rather than
its presence was a more important confounder, possibly as the
Table 2. Number and rate of influenza like illness (ILI) cases.
Age category
,=4 5–19 20–49 50–59 60–79 80+
Number of ILI cases (%) 4 (0.31%) 24 (0.26%) 59 (0.27%) 29 (0.20%) 112 (0.18%) 27 (0.21%)
Person Time1 268 1839 4319 2982 13106 2714
Incidence Rate (95%CI)2 14.9 (5.60–39.73) 13.1 (8.75–19.47) 13.7 (10.58–17.63) 9.7 (6.76–13.99) 8.6 (7.10–10.28) 9.9 (6.82–14.50)
1In years.
2per 1,000 person- years.
doi:10.1371/journal.pone.0063156.t002
Table 3. Crude and adjusted pandemic H1N1 vaccine effectiveness per age category: Primary analysis with baseline at 30-11-2009
& Post hoc Time Dependent Analysis with baseline at 01-10-2009.
Age Category Number of ILI cases (%) Crude VE 95%CI Adjusted VE* 95%CI
Overall 17.3% 28.5% to 36.9% 20.8% 25.4% to 40.5%
,=4 yrs 4 (0.31%) 2482.9% 26988.3% to 52.1% 2505.8% 28341.8% to 56.5%
5–19 yrs 24 (0.26%) 38.7% 285.4% to 79.8% 50.9% 251.0% to 84.0%
20–49 yrs 59 (0.27%) 42.2% 27.1% to 68.8% 58.7% 22.7% to 77.9%
50–59 yrs 29 (0.20%) 17.7% 279.4% to 62.3% 20.9% 276.1% to 64.5%
60–79 yrs 112 (0.18%) 236% 2122% to 16% 214,2% 286.7% to 30.1%
80+yrs 27 (0.21%) 12% 2114% to 64% 18,3% 2100.7% to 66.8%
doi:10.1371/journal.pone.0063156.t003
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majority of persons in the cohort had underlying medical
conditions. The approximation used for determining severity of
disease by number of different pharmaceutical compounds
prescribed is a crude measure that should be further refined and
validated for future influenza vaccine effectiveness studies. Also,
other methods of mapping severity of underlying co-morbidity
remain to be evaluated. Given the large effect of disease severity,
misclassification of this covariate can be an important source of
residual confounding.
Being a study using observational data, misclassification and
residual confounding are a potential concern. As the likelihood of
being exposed increased when moving away from the epidemic
peak, and the likelihood of ILI (and the specificity of ILI to
represent influenza infection) decreased away from the peak we
chose the start of follow-up where the majority of vaccinated
persons had received at least one dose of influenza
A(H1N1)pdm09 vaccine and there was still detectable influenza
transmission in the community. This had two major consequences
– it limited the power of the study, and misclassification of
exposure was inevitable. We evaluated the effect of time since
exposure by only considering those exposed who received a first
dose more than 7 or 14 days before baseline. This did have a
considerable impact on the estimate of VE, decreasing it from
17.3% to 13.3% (95%CI: 215.5%, 34.9%) and 5.1% (95%CI:
236.1%, 33.8%) respectively. The reduction in VE when
including the time restriction to define exposed status illustrates
how misclassification of exposure dilutes the estimate in our study.
As the majority of vaccinated persons had received their first dose
(table 1) at start of follow-up we hope to have minimized the
consequences of exposure misclassification. This was further
supported by the analysis in which exposure was considered as a
time dependent variable. An increase in power and shift in effect
estimate was seen in children under five years, however not in
other age groups indicating only limited misclassification of
exposure overall.
Misclassification of exposure also may have occurred since
recording of influenza vaccinations in the patient record by the GP
was not compulsory and vaccinations could have been obtained
through other sources. To minimize such misclassification we
excluded GPs with ambiguous vaccine registration in the
electronic patient record. We did miss vaccinations in children
below 5, and in health care workers who received vaccinations
elsewhere than at the GP. This misclassification most likely would
drive the VE toward no effect.
We varied the start of follow-up to evaluate the impact of
calendar time on the study. The crude VE increased to 23%
(95%CI: 4%, 38%) when applying an earlier start date (week 47),
and decreased to 27.8% (95%CI: 248.0%, 22.4%) when
applying a later start of follow-up (week 51), illustrating that the
specificity of medically attended ILI changed during the epidemic.
False-negative misclassification of ILI is likely to have occurred
since people were advised to stay at home and not contact the GP
with flu symptoms. Differential misclassification may have arisen if
people with more serious underlying disease were more likely than
other people to get the vaccination and to report ILI to their GP,
leading to an underestimation of the VE.
Conclusion
With our study we demonstrated that the approach of
combining a cohort study in a primary health care database with
field sampling is a feasible option to monitor VE of influenza
vaccines in the future. This approach had the benefit of reliably
measuring the presence of a large number of potential confound-
ing variables, including underlying comorbidities, severity of
disease, health seeking behavior, drug use patterns and vaccination
history and evaluating their effect on VE estimates whilst
validating the less specific outcomes that are measurable in the
cohort, such as ILI, with more specific laboratory confirmed
outcomes.
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